{{undue|date=2017年10月}}
{{NoteTA
| G1=Medicine
| G2=Lifesciences
| T= zh-cn:注意（力）缺陷多动障碍的争议; zh-tw:注意力不足過動症的爭議; zh-hk:專注力失調（或）過度活躍症的爭議;
| 1= zh-cn:注意力缺陷多动障碍; zh-tw:注意力不足過動症; zh-hk:專注力失調或過度活躍症;
}}
{{medical}}
[[File:Ritalin_Pill.jpg|thumb]]（利他能）的藥錠（Ciba/Novartis），是常用來治療ADHD的處方藥]]
自1970年代開始，[[注意力不足過動症|注意力不足過動症]]（ADHD）疾病本身、其診斷及醫療在[[歐美|歐美]]就已經是有爭議性的議題<ref name="Parrillo 2008 63">{{Cite book | title=Encyclopedia of Social Problems | author=Parrillo VN | year=2008 | publisher=SAGE | isbn=9781412941655 | page=63 | url=https://books.google.com/?id=mRGr_B4Y1CEC | accessdate=2009-05-02 }}</ref><ref name="autogenerated3">{{cite journal |vauthors=Mayes R, Bagwell C, Erkulwater J | title = ADHD and the rise in stimulant use among children | journal = Harv Rev Psychiatry | volume = 16 | issue = 3 | pages = 151–166 | date = 2008 | pmid = 18569037 | doi = 10.1080/10673220802167782 }}</ref><ref>{{Cite journal|author=Foreman DM |title=Attention deficit hyperactivity disorder: legal and ethical aspects |journal=Archives of Disease in Childhood |volume=91 |issue=2 |pages=192–194 |date=2006-02 |pmid=16428370 |pmc=2082674 |doi=10.1136/adc.2004.064576}}</ref>。爭議和臨床醫師、教師、政策訂定者、家長及媒體有關。各觀點對注意力不足過動症的認知差異很大，有的認為注意力不足過動症是正常行為的範圍內<ref name=NICE2009-part2>{{cite book |title=Attention Deficit Hyperactivity Disorder: Diagnosis and Management of ADHD in Children, Young People and Adults |author=National Collaborating Centre for Mental Health |series=NICE Clinical Guidelines |volume=72 |publisher=British Psychological Society |location=Leicester |isbn=978-1-85433-471-8 |date=2009 |url=https://www.ncbi.nlm.nih.gov/books/NBK53652/ |chapter=Attention Deficit Hyperactivity Disorder |pages=[https://www.ncbi.nlm.nih.gov/books/NBK53663/#ch2.s8 18–26], [https://www.ncbi.nlm.nih.gov/books/NBK53663/#ch2.s41 38] |chapter-url=https://www.ncbi.nlm.nih.gov/books/NBK53663/ |via=NCBI Bookshelf |access-date=2017-06-22 |archive-url=https://web.archive.org/web/20160113133612/http://www.ncbi.nlm.nih.gov/books/NBK53652/ |archive-date=2016-01-13 |dead-url=no }}</ref><ref name="Faraone 2005">{{cite journal |last=Faraone |first=Stephen V. |date=2005-02 | title = The scientific foundation for understanding attention-deficit/hyperactivity disorder as a valid psychiatric disorder |journal=European Child & Adolescent Psychiatry | volume = 14 | issue = 1| pages = 1–10 | pmid = 15756510 |doi=10.1007/s00787-005-0429-z |subscription=yes }}</ref>，也有的假定注意力不足過動症是一種遺傳疾病<ref>{{cite news|last1=Boseley|first1=Sarah|title=Hyperactive children may suffer from genetic disorder, says study|url=https://www.theguardian.com/society/2010/sep/30/hyperactive-children-genetic-disorder-study|newspaper=The Guardian|date=2010-09-30|access-date=2017-06-29|archive-url=https://web.archive.org/web/20170708164457/https://www.theguardian.com/society/2010/sep/30/hyperactive-children-genetic-disorder-study|archive-date=2017-07-08|dead-url=no}}</ref>。其他有關注意力不足過動症的爭議包括對兒童用（合理劑量的）中樞神經刺激劑藥物進行治療<ref name="autogenerated3"/><ref name=Cormier2008/>、診斷的方式，以及是否有{{le|過度診斷|Overdiagnosis}}或診斷不足的情形<ref name=Cormier2008>{{cite journal |last=Cormier |first=Eileen |title=Attention deficit/hyperactivity disorder: a review and update |journal=Journal of Pediatric Nursing |volume=23 |issue=5 |pages=345–57 |date=2008-10 |pmid=18804015 |doi=10.1016/j.pedn.2008.01.003|url=http://linkinghub.elsevier.com/retrieve/pii/S0882-5963(08)00005-5 |url-access=subscription }}</ref>。{{le|英國國家健康照護專業組織|National Institute for Health and Care Excellence}}（NICE）在2009年發表聲明，聲明中有提及目前存在的爭議，也表示：目前的治療及診斷方式都是依照學術文獻中的主流學術觀點為基礎<ref name=NICE2009-Diagnosis>{{cite book |title=Attention Deficit Hyperactivity Disorder: Diagnosis and Management of ADHD in Children, Young People and Adults |author=National Collaborating Centre for Mental Health |series=NICE Clinical Guidelines |volume=72 |publisher=British Psychological Society |location=Leicester |isbn=978-1-85433-471-8 |date=2009 |url=https://www.ncbi.nlm.nih.gov/books/NBK53652/ |chapter=Diagnosis |pages=[https://www.ncbi.nlm.nih.gov/books/NBK53659/#ch5.s40 116–7], [https://www.ncbi.nlm.nih.gov/books/NBK53659/#ch5.s42 119] |chapter-url=https://www.ncbi.nlm.nih.gov/books/NBK53659/ |via=NCBI Bookshelf |access-date=2017-06-22 |archive-url=https://web.archive.org/web/20160113133612/http://www.ncbi.nlm.nih.gov/books/NBK53652/ |archive-date=2016-01-13 |dead-url=no }}</ref>。2014年時，[[基思·康納斯|基思·康納斯]]（是早期推動美國大眾認知注意力不足過動症的人士之一），在《[[紐約時報|紐約時報]]》提出他認為注意力不足過動症在美國有過度診斷的情形<ref name=NYT2013>{{cite news|last1=Schwarz|first1=Alan|title=The Selling of Attention Deficit Disorder|url=https://www.nytimes.com/2013/12/15/health/the-selling-of-attention-deficit-disorder.html|accessdate=2015-02-26|issue=2013-12-14|newspaper=The New York Times|date=2013-12-14|archive-url=https://web.archive.org/web/20150301054334/http://www.nytimes.com/2013/12/15/health/the-selling-of-attention-deficit-disorder.html|archive-date=2015-03-01|dead-url=no}}</ref>，不過同年有一篇經過[[同儕審查|同儕審查]]的醫學回顧性文獻，表明ADHD在美國成人族群中的診斷率低於實際的[[盛行率|盛行率]]<ref name="underdiagnosed">{{cite journal | vauthors = Ginsberg Y, Quintero J, Anand E, Casillas M, Upadhyaya HP | title = Underdiagnosis of attention-deficit/hyperactivity disorder in adult patients: a review of the literature | journal = Prim Care Companion CNS Disord | volume = 16 | issue = 3 | pages = | year = 2014 | pmid = 25317367 | pmc = 4195639 | doi = 10.4088/PCC.13r01600 | quote = Reports indicate that ADHD affects 2.5%–5% of adults in the general population,<sup>5–8</sup> compared with 5%–7% of children.<sup>9,10</sup> ... However, fewer than 20% of adults with ADHD are currently diagnosed and/or treated by psychiatrists.<sup>7,15,16</sup>}}</ref>。

ADHD的診斷率在各國家、同一國家的不同地區、種族及族群之間有著相當的差異，因此除了ADHD的盛行率外，可能也有其他因素影響ADHD的診斷<ref name="Elder-2010">{{cite journal | author = Elder TE | title = The importance of relative standards in ADHD diagnoses: evidence based on exact birth dates | journal = J Health Econ | volume = 29 | issue = 5 | pages = 641–656 |date=2010-09  | pmid = 20638739 | pmc = 2933294 | doi = 10.1016/j.jhealeco.2010.06.003 | url = }}</ref><ref>{{cite journal | author = Alaa M. Hamed,1 Aaron J. Kauer,1 and Hanna E. Stevens | title = Why the Diagnosis of Attention Deficit Hyperactivity Disorder Matters | journal = Front Psychiatry | date = 2015-11-26 | pmc = 4659921 | doi = 10.3389/fpsyt.2015.00168 | url = https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659921/ | access-date = 2017-06-29 | archive-url = https://web.archive.org/web/20170628222040/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659921/ | archive-date = 2017-06-28 | dead-url = no }}</ref>。部份[[社會學|社會學家]]認為ADHD是將「不常見且不被廣泛接受的行為」[[醫療化|醫療化]]的例子，也就是將一些以往認為和醫學無關的學校表現問題，用醫療的方式來處理<ref name="Parrillo 2008 63"/><ref name=Erk2009>{{cite book |vauthors=Mayes R, Bagwell C, Erkulwater JL | title=Medicating Children: ADHD and Pediatric Mental Health | publisher=Harvard University Press | date=2009 | pages=4–24 | isbn=978-0-674-03163-0 | edition=illustrated }}</ref>。在美國，大部份的醫療人員認為ADHD是真正的疾病，至少在症狀較明顯的人身上是這樣沒錯<ref name=Erk2009/>；而美國醫療人員之間仍存在的爭議主要是在那些較多數，症狀較輕微的病症的診斷及治療方式<ref name="Online">{{cite book| author=Silver LB |title=Attention-deficit/hyperactivity disorder | publisher=American Psychiatric Publishing | edition=3rd | year=2004 | isbn=978-1-58562-131-6 | pages=4–7 }}</ref><ref name="Schonwald">{{cite journal |vauthors=Schonwald A, Lechner E | title = Attention deficit/hyperactivity disorder: complexities and controversies | journal = Curr. Opin. Pediatr. | volume = 18 | issue = 2 | pages = 189–195 | date = 2006-04 | pmid = 16601502 | doi = 10.1097/01.mop.0000193302.70882.70 }}</ref><ref name=Erk2009/><ref name=NYT2013/>，另外一些爭議是在於ADHD是否有過度診斷或是診斷不足的情形<ref>{{cite journal|last1=Merten|first1=EC|last2=Cwik|first2=JC|last3=Margraf|first3=J|last4=Schneider|first4=S|title=Overdiagnosis of mental disorders in children and adolescents (in developed countries).|journal=Child and adolescent psychiatry and mental health|date=2017|volume=11|pages=5|pmid=28105068|pmc=5240230}}</ref><ref>{{cite journal|last1=Taylor|first1=E|title=Attention deficit hyperactivity disorder: overdiagnosed or diagnoses missed?|journal=Archives of disease in childhood|date=2017-04|volume=102|issue=4|pages=376-379|doi=10.1136/archdischild-2016-310487|pmid=27821518}}</ref>。台灣在2016年7月時，因為ADHD是否要用藥的爭議，[[立法院|立法院]]舉行過「ADHD之多元探討公聽會」。

==簡介==
根據[[美國精神醫學學會|美國精神醫學學會]]在2013年出版的{{le|精神疾病診斷與統計手冊第5版|DSM-5|《精神疾病診斷與統計手冊》第5版}}（DSM-5），注意力不足過動症屬於[[神經發育障礙|神經發育障礙]]，在大部份文化下，兒童的[[盛行率|盛行率]]為5%、成人的盛行率為2.5%<ref name=Sim/><ref name=dsm5>{{citation|author=American Psychiatric Association|title=Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition|url=https://books.google.com/books?id=-JivBAAAQBAJ&lpg=PT1022&dq=%22dsm-5%22&pg=PT157#v=onepage&q=adhd%20prevalence&f=false|year=2013|publisher=American Psychiatric Association: Arlington, VA|isbn=9780890425572}}</ref>。現今注意力不足過動症此一疾病的存在是廣為人接受的事實<ref name=Sim/>，不過有關此一疾病的爭議在1970年代就已經開始<ref name=parrillo>{{citation|last=Parrillo|first=VN|title=Encyclopedia of Social Problems, Volume 1|url=https://books.google.com/books?id=mRGr_B4Y1CEC&lpg=PP1&dq=percent%20who%20consider%20ADHD%20controversial&pg=PT107#v=onepage&q=adhd%20controversial&f=false|publisher=SAGE|year=2008|page=63|accessdate=2016-04-07|isbn=9781412941655}}</ref>。成人注意力不足過動症繼續成為爭議的來源之一<ref name=parrillo/>。根據DSM-5，相關症狀需在12歲以前就出現，但是注意力不足過動症的症狀常常持續到成人階段<ref name=dsm5/>。一些家長及教育者仍會懷疑兒童是否有{{le|過度診斷|overdiagnosis}}的情形，以及治療方式的有效程度，特別是包括中樞神經刺激劑（興奮劑，下同）在內的藥物治療<ref name=Sim>{{cite journal |vauthors=Sim MG, Hulse G, Khong E |title=When the child with ADHD grows up |journal=Australian Family Physician |volume=33 |issue=8 |pages=615–8 |date=2004-08|pmid=15373378}}</ref><ref name=parrillo/><ref name=Mayes2008>{{cite journal |vauthors=Mayes R, Bagwell C, Erkulwater J |title=ADHD and the rise in stimulant use among children |journal=Harvard Review of Psychiatry |volume=16 |issue=3 |pages=151–66 |year=2008 |pmid=18569037 |doi=10.1080/10673220802167782 }}</ref>。不過根據社會學教授{{le|Vincent N. Parrillo|Vincent N. Parrillo}}表示：「家長以及像是CHADD（即ADHD兒童及成人患者）等團體仍傾向支持醫學界對於注意力不足過動症的觀點。」<ref name=parrillo/>

==成因==
注意力不足過動症的病理生理學還不清楚，也存在著許多相互競爭的理論<ref>{{cite web |url=http://www.uptodate.com/online/content/topic.do?topicKey=behavior/8293&selectedTitle=4~150&source=search_result |title=Evaluation and diagnosis of attention deficit hyperactivity disorder in children |accessdate=2008-09-15 |work= |publisher= |date=2007-12-05 |archive-url=https://web.archive.org/web/20090605040840/http://www.uptodate.com/online/content/topic.do?topicKey=behavior%2F8293&selectedTitle=4~150&source=search_result |archive-date=2009-06-05 |dead-url=no }}</ref>。
===將ADHD視為是生理造成的疾病===
已經發現在注意力不足過動症患者及非患者的大腦有些差異，而且常常可以觀察到其中的差異<ref name="pmid22851201">{{cite journal |vauthors=Cortese S, Castellanos FX |title=Neuroimaging of attention-deficit/hyperactivity disorder: current neuroscience-informed perspectives for clinicians |journal=Curr Psychiatry Rep |volume=14 |issue=5 |pages=568–78 |date=2012-10 |pmid=22851201 |pmc=3876939 |doi=10.1007/s11920-012-0310-y }}</ref>，但還不確定是否是這些差異造成[[注意力不足過動症#特徵和症狀|注意力不足過動症的症狀]]，也還不知道這些差異如何導致相關的症狀。許多不同種類[[神经成像|神经成像]]的結果指出注意力不足過動症患者及非患者的大腦是有差異的，例如患者的[[大脑皮质|大脑皮质]]有較薄的區域等。<ref>{{cite journal |author1=Philip Shaw |author2=Jason Lerch |author3=Deanna Greenstein |author4=Wendy Sharp |author5=Liv Clasen |author6=Alan Evans |author7=Jay Giedd |author8=F. Xavier Castellanos |author9=Judith Rapoport |title=Longitudinal Mapping of Cortical Thickness and Clinical Outcome in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder |journal=Arch Gen Psychiatry |volume=63 |pages=540–549 |year=2006|pmid=16651511 |doi=10.1001/archpsyc.63.5.540}}</ref>。

一般認為注意力不足過動症有高度的遺傳性。[[双生子研究|双生子研究]]結果指出：注意力不足過動症的變異中，有約70至80%可以用基因來說明<ref>{{Cite journal|last=Nikolas|first=Molly A.|last2=Burt|first2=S. Alexandra|date=2010-02-01|title=Genetic and environmental influences on ADHD symptom dimensions of inattention and hyperactivity: a meta-analysis|journal=Journal of Abnormal Psychology|volume=119|issue=1|pages=1–17|doi=10.1037/a0018010|issn=1939-1846|pmid=20141238}}</ref>，不過目前也有較多研究在探討，基因-環境交互作用是否對注意力不足過動症有影響，母親吸煙或是喝酒可能是影響因素之一<ref>{{Cite journal|last=Thapar|first=Anita|last2=Stergiakouli|first2=Evangelia|date=2017-05-08|title=An Overview on the Genetics of ADHD|journal=Xin li xue bao. Acta psychologica Sinica|volume=40|issue=10|pages=1088–1098|doi=10.3724/SP.J.1041.2008.01088|issn=0439-755X|pmc=2854824|pmid=20396407}}</ref>。也有人認為注意力不足過動症其實是{{le|等位异质性|Allelic heterogeneity|異質性}}疾病<ref name="Barkley">{{cite web|url=http://www.continuingedcourses.net/active/courses/course003.php|title=Attention-Deficit/Hyperactivity Disorder: Nature, Course, Outcomes, and Comorbidity|last=Barkley|first=Russel A.|accessdate=2006-06-26|archive-url=https://web.archive.org/web/20060810070433/http://www.continuingedcourses.net/active/courses/course003.php|archive-date=2006-08-10|dead-url=no}}</ref>，其中有多種遺傳及環境的因素，結果是產生類似的基因變化。2014年一篇ADHD病因綜述的作者提到：「雖然[[全基因组关联分析|全基因组关联分析]]已識別出一些染色體區域，其中可能包括會造成ADHD易感性的基因，目前為止還沒有識別出哪一個單獨的基因是主要造成ADHD的原因。」<ref>{{cite journal |author1=M. T. Acosta |author2=M. Arcos-Burgos |author3=M. Muenke | title=Attention deficit/hyperactivity disorder (ADHD): Complex phenotype, simple genotype? | journal=Genetics in Medicine | year=2004 | volume=6 | issue=1 | pages= 1–15 | doi=10.1097/01.GIM.0000110413.07490.0B | pmid=14726804}}</ref>。不過那篇病因綜述之後又有許多新的研究，而其他其他可遺傳的人類特徵（例如[[思覺失調症|思覺失調症]]）也有類似的{{le|遺失遺傳問題|Missing heritability problem}}，其特徵無法用單一基因來解釋。在線孟德爾遺傳（Online Mendelian Inheritance in Man, OMIM）數據庫列出了常染色體顯性遺傳狀態下，有關ADHD的基因，聲稱這些基因會造成ADHD。到2014年為止，OMIM列出了六個基因（以及其變體）和ADHD有關<ref>{{cite web|url=http://omim.org/entry/143465 |title=Attention deficit-hyperactivity disorder; ADHD |work=Online Medelian Inheritance in Man |accessdate=2014-05-14 }}{{dead link|date=2016-10 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>。

===ADHD的社會建構理論===
<!--{{Main article|Social construct theory of ADHD}}-->
{{le|注意力不足過動症的社會建構理論|Social construct theory of ADHD}}認為注意力不足過動症不一定是真正的[[疾病|疾病]]，而注意力不足過動症的[[診斷|診斷]]是[[社會建構主義|社會建構]]的解釋，只是描述一些不符合一般認知[[社會規範|社會規範]]的行為<ref>{{cite journal |vauthors=Parens E, Johnston J |title=Facts, values, and Attention-Deficit Hyperactivity Disorder (ADHD): an update on the controversies |journal=Child Adolesc Psychiatry Ment Health |volume=3 |issue=1 |pages=1|year=2009 |pmid=19152690|pmc=2637252 |doi=10.1186/1753-2000-3-1 |url=}}</ref>。

也有論點提出，就算ADHD是社會建構的，ADHD仍然可以是實際存在的疾病，就像[[肥胖|肥胖]]是由許多不同的文化構成，而其本身仍然是疾病，對身體也有明顯的不良效果<ref>{{cite journal|author= Parens, Erik|year= 2009|title= Facts, values, and Attention-Deficit Hyperactivity Disorder (ADHD): an update on the controversies|journal= Child and Adolescent Psychiatry and Mental Health|volume= 3|series= |issue= 1|page= |pages= 1|publisher= |location= |pmid= 19152690|url= http://www.capmh.com/content/3/1/1|doi= 10.1186/1753-2000-3-1|last2= Johnston|first2= J|pmc= 2637252|access-date= 2009-08-20|archive-url= https://web.archive.org/web/20100506124831/http://www.capmh.com/content/3/1/1|archive-date= 2010-05-06|dead-url= no}}</ref>。支持ADHD社會建構理論的人，有少數認為ADHD「是被人為發明出來的疾病」，他們認為其實沒有ADHD疾病<ref>{{cite book|author=Richard Saul |coauthors=林雨蒨 譯 |title=ADHD並不存在：過動症跟你想像的不一樣！ |year=2014 |publisher=小樹文化 |location=台北市 |isbn=9789865837242 |date=2014-11-01 |accessdate=2017-07-11 }}</ref>，而所觀察到的行為可能是因為其他原因或是疾病而出現<ref>{{cite web |url=http://pansci.asia/archives/83259 |language=中文 |title=注意力不足過動症（ADHD）到底存不存在？ |publisher=泛科學 |date=2014-10-01 |accessdate=2017-07-13 |archive-url=https://web.archive.org/web/20170318062246/http://pansci.asia/archives/83259 |archive-date=2017-03-18 |dead-url=no }}</ref>。

==診斷==
===診斷方式===
目前沒有可以診斷注意力不足過動症的血液檢查或是腦部掃描。診斷是透過臨床上和兒童及家長的面談為基礎<ref>[http://www.pbs.org/wgbh/pages/frontline/shows/medicating/interviews/diller.html medicating kids: interviews: dr. lawrence diller] {{webarchive |url=https://web.archive.org/web/20160420082009/http://www.pbs.org/wgbh/pages/frontline/shows/medicating/interviews/diller.html |date=2016-04-20 }} PBS - Frontline</ref>。

過去的二十年中，已有許多針對腦部機能的研究，可以支持「注意力不足過動症是执行功能障碍的问题」的論點<ref>{{Cite journal|url = |title = The neurobiological profile of girls with ADHD|author1=Mahone, E. M. |author2= Wodka, E. L. |last-author-amp=yes |date = 2008|journal = Developmental Disabilities Research Reviews|doi = 10.1002/ddrr.41|pmid = |volume=14 |issue = 4|pages=276–284}}</ref>。男性和女性的大腦有些差異，可能可以解釋ADHD在男性及女性身上的症狀可能會有不同之處。針對男孩及女孩的腦電圖進行的研究表明，在識別ADHD時，不能忽略男孩和女孩的性別差異。男孩和女性在其成熟模式下，兩者的腦電圖之間有些差異，因此可能要針對ADHD的性別差異作進一步的探討及研究<ref>{{Cite journal|url = |title = Sex differences between the combined and inattentive types of attention-deficit/hyperactivity disorder: An EEG perspective|author1=Dupuy, F. E. |author2=Barry, R. J. |author3=Clarke, A. R. |author4=McCarthy, R. |author5= Selikowitz, M. |last-author-amp=yes|date = 2013|journal = International Journal of Psychophysiology|doi = 10.1016/j.ijpsycho.2013.04.004|pmid = |volume=89 |issue = 3|pages=320–327}}</ref>。

===過度診斷及診斷不足===
ADHD的過度診斷一般是指兒童沒有ADHD，但被診斷患有ADHD。這類的情形會稱為「[[偽陽性|偽陽性]]」，不過「單單出現診斷上的偽陽性，不表示有過度診斷的情形」，若診斷方式本身有不精確，或是其盛行率持續有偏高的情形，才能說是過度診斷。「若ADHD有過度診斷的情形，偽陽性的比例需明顯的大於[[偽陰性|偽陰性]]（兒童有ADHD，但沒有識別或是診斷出來）的比例」<ref name="Sciutto, M. J. 2007">{{cite journal | author = Sciutto M. J., Eisenberg M. | year = 2007 | title = Evaluating the Evidence For and Against the Overdiagnosis of ADHD | url = | journal = Journal of Attention Disorders | volume = 11 | issue = 2| pages = 106–113 | doi=10.1177/1087054707300094}}</ref>。一般8至15歲的兒童，ADHD盛行率約為7.8%，但只有48%的患者在十二個月內有接受精神衛生醫療<ref>{{cite journal |last= Connor |first= DF |title= Problems of overdiagnosis and overprescribing in ADHD |journal= Psychiatric Times |volume= 28 |issue= 8 |year= 2011 |pages= 14–8}}</ref>。

證據也指出ADHD的盛行率在不同的種族及族群中也可能有些差異。儘管使用相同的方式進行分析，ADHD在不同文化下的盛行率會有很大的變化，有些研究者認認為這是因為不同文化對於什麼情形才算是破壞行為、不專心和多動症有不同的看法<ref name="Cuffe, S. P. 2005">{{cite journal |last1= Cuffe |first1= SP |last2= Moore |first2= CG |last3= McKeown |first3= RE |year= 2005 |title= Prevalence and correlates of ADHD symptoms in the National Health Interview Survey |journal= Journal of Attention Disorders |volume= 9 |issue= 2 |pages= 392–401 |doi=10.1177/1087054705280413|pmid= 16371662 }}</ref>。

有研究者認為過度診斷發生在富裕或同質性高的社區，而較貧窮或是較弱勢的社區因為缺乏資源，也沒有財務支應，比較容易出現診斷不足的情形。沒有醫療保險的人比較不容易針對ADHD就診。再進一步地，「ADHD診斷的分布會沿著社會經濟線的分界」<!--according to the amount of wealth within a neighborhood.-->。因此很難將全國性、通用的指南應用到地區性、個別的情形，例如無法轉診、缺乏資源或是病人沒有保險的情形，都會助長ADHD的誤診<ref>{{cite journal |last= Morely |first= CP |year= 2010 |title= Disparities in ADHD assessment, diagnosis and treatment |journal= International Journal of Psychiatry in Medicine |volume= 40 |issue= 4 |pages= 383–9|pmid= 21391409 }}</ref>。

病患的發展情形也會影響對於ADHD狀態的認知。一般認為ADHD是慢性疾病，在兒童期出現，會延續到成人期。不過有些研究者發現當兒童的ADHD病患長大進入成年時，有些病患的症狀會減退。當兒童進入青春期時，家長和老師開始將關注的焦點轉向會影響學業表現的行為。有些研究指出ADHD的主要症狀是家長針對病患評估的主要鑒別診斷基準，但不同年齡層的病患，其主要鑒別診斷基準也有所不同。兒童ADHD病患的主要鑒別診斷基準是過動，而青少年病患的主要鑒別診斷基準是無法專注<ref name="Harrison, J. R. 2011">{{cite journal |last1= Harrison |first1= JR |last2= Vannest |first2= KJ |last3= Reynolds |first3= CR |year= 2011 |title= Behaviors that discriminate ADHD in children and adolescents: Primary symptoms, symptoms of comorbid conditions or indicators of functional impairment? |journal= Journal of Attention Disorders |volume= 15 |issue= 2 |pages= 147–60 |doi=10.1177/1087054709356170|pmid= 20354233 }}</ref>。

合併症的問題也是另一個解釋ADHD過度診斷的原因。在確診ADHD的兒童中，有75%符合其他精神精神科的诊断标准<ref name="Cuffe, S. P. 2005"/>。確診ADHD的兒童中，有25%至30%有焦虑症、有9%至32%有抑郁症、45%至84%有{{le|對立性違抗症|oppositional defiant disorder}}，而44%至55%青少年的病患有品行障碍<ref name="Harrison, J. R. 2011"/>，ADHD的兒童病患中有20%至40%有學習障礙<ref name="Cuffe, S. P. 2005"/>。

另一種ADHD過度診斷的可能解釋是出現在兒童身上的「{{le|相對年齡效應|Relative age effect}}」。同一年級中，實際年齡較小的兒童比較容易誤診為ADHD，並且用處方藥物進行治療，相對的，同年級實際年齡較大的兒童比較不會有此情形。若兒童比其同年級的同學小了將近一歲，往往會比其他同學要來的不成熟，也會影響其学业和运动表现<ref name=CMAJ>{{cite journal |last= Morrow |first= R |last2= Garland |first2= J |last3= Wright |first3= J |last4= Maclure |first4= M |last5= Taylor |first5= S |last6= Dormuth |first6= C |displayauthors= 4 |title= Influence of relative age on diagnosis and treatment of Attention-Deficit/Hyperactivity Disorder in children |journal= Canadian Medical Association Journal |date= 17 April 2012 |volume= 184 |issue= 7 |pages= 755–62 |url= http://www.cmaj.ca/content/184/7/755.full.pdf+html |doi= 10.1503/cmaj.111619 |pmid= 22392937 |pmc= 3328520 |author=  |access-date= 2013-11-22 |archive-url= https://web.archive.org/web/20140102165917/http://www.cmaj.ca/content/184/7/755.full.pdf+html |archive-date= 2014-01-02 |dead-url= no }}</ref>。2017年11月時，[[刺胳針|刺胳針]]針對其他國家的的研究發現，上述現象在七到九歲這個時期比較明顯<ref name="Sayal Chudal Hinkka-Yli-Salomäki Joelsson 2017 pp. 868–875">{{cite journal | last=Sayal | first=Kapil | last2=Chudal | first2=Roshan | last3=Hinkka-Yli-Salomäki | first3=Susanna | last4=Joelsson | first4=Petteri | last5=Sourander | first5=Andre | title=Relative age within the school year and diagnosis of attention-deficit hyperactivity disorder: a nationwide population-based study | journal=The Lancet Psychiatry | volume=4 | issue=11 | date=2017-11-01 | issn=2215-0366 | pmid=29033006 | doi=10.1016/S2215-0366(17)30394-2 | pages=868–875 | url=https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(17)30394-2/abstract | access-date=2018-10-02}}</ref>。

有關ADHD診斷不足（或稱為「偽陰性」）的探討主要是出現在探討成人、女孩或是弱勢族群ADHD的文獻中。估計在成人中，ADHD的比例約在4%至6%之間<ref>{{cite journal |last1= Able |first1= SL |last2= Johnston |first2= JA |last3= Adler |first3= LA |last4= Swindle |first4= RW |year= 2007 |title= Functional and psychosocial impairment in adults with undiagnosed ADHD |journal= Psychological Medicine |issue= 1 |pages= 97–107 | doi = 10.1017/s0033291706008713 |pmid= 16938146 |volume=37}}</ref>。不過成人的ADHD病患中，只有11%有真正得到評估以及治療<ref>{{cite journal |last1= Kessler |first1= RC |last2= Adler |first2= L |last3= Barley |first3= R |last4= Biederman |first4= J |last5= Conners |first5= CK |last6= Demler |first6= O |displayauthors= 4 |year= 2006 |title= The prevalence and correlates of adult ADHD in the United States: Results  from the National Comorbidity Survey Replication |journal= The American Journal of Psychiatry |volume= 163 |issue= 4 |pages= 716–23 |pmid= 16585449|doi= 10.1176/appi.ajp.163.4.716 |pmc=2859678}}</ref>。有ADHD症狀的兒童，到成人時，有30%至70%不等的比例有出現ADHD的損害性症狀、而30%至50%仍符合ADHD診斷的標準<ref>{{cite journal |last= Manos |first= MJ |year= 2010 |title= Nuances of assessment and treatment of ADHD in adults: A guide for psychologists |journal= Professional Psychology: Research and Practice |volume= 41 |issue= 6 |pages= 511–7 |doi=10.1037/a0021476}}</ref>。

有關ADHD性別差異的研究也指出了在ADHD女孩有診斷不足的問題。ADHD的男女比例為4:1，而罹患ADHD的女孩中，有92%是注意力不足的亞型<ref name="Cuffe, S. P. 2005"/>。這個性別上的差異可以用ADHD在男孩及女孩身上出現不同的症狀來解釋<ref name="Bruchmuller, K. 2012">{{cite journal |last1= Bruchmuller |first1= K |last2= Margraf |first2= J |last3= Schneider |first3= S |year= 2012 |title= Is ADHD diagnosed in accord with diagnostic criteria? Overdiagnosis and influence of client gender on diagnosis |journal= Journal of Counseling and Clinical Psychology |volume= 80 |issue= 1 |pages= 128–38 |doi=10.1037/a0026582 |pmid=22201328}}</ref>。一般而言，ADHD的女性比較不會有破坏性行为，比較多的是[[内化|内化行為]]<ref name="Sciutto, M. J. 2007"/><ref name = Beiderman/>。相較於有相同疾病的男孩，ADHD的女孩多半比較不會有行為上的問題，較不會有侵略行为，比較不會冲动及過動的行為。ADHD女孩的行為模式比較不會影響課堂或是家庭生活，因此家長或是老師比較可能低估或是忽略這一方面的潛在問題<ref name="Bruchmuller, K. 2012"/>。目前的診斷準則比較是以男性為主，較少考慮到女性的情形，因此比較會強調男性ADHD的一些症狀特徵<ref>{{cite journal|last=Hinshaw|first=S|first2=E|last2=Owens|first3=C|last3=Zalecki|title=Prospective follow-up of girls with Attention-Deficit/ Hyperactivity Disorder into early adulthood: Continuing impairment includes elevated risk for suicide attempts and self-Injury|journal=American Psychology Association|date=2012|volume=80|issue=6|pages=1041–1051|doi=10.1037/a0029451|url=http://www.apa.org/pubs/journals/releases/ccp-80-6-1041.pdf|author=|access-date=2014-04-21|archive-url=https://web.archive.org/web/20130923125601/http://www.apa.org/pubs/journals/releases/ccp-80-6-1041.pdf|archive-date=2013-09-23|dead-url=no}}</ref>。因此有許多ADHD的女孩或是女性被忽略了。研究發現有ADHD的女孩，尤其是那些冲动迹象的女孩，其試圖自殺的比例是有對照組女孩（沒有類似症狀的女孩）的三到四倍，而且這些女性自傷的比例也是其他女性的二到三倍<ref name = Beiderman>{{cite journal|last=Beiderman, J.|first=Joseph|author2=Stephen Farone |author3=Eric Mick |title=Clinical correlates of ADHD in females: Findings from a large group of girls ascertained from pediatric and psychiatric referral sources|journal=Journal of the American Academy of Child and Adolescent Psychiatry|date=1999|volume=38|issue=8|pages=966–975|doi=10.1097/00004583-199908000-00012}}</ref>。

如同之前所提到的，一般認為ADHD的診斷不足比較容易出現在弱勢的社群中，這些社群一般也比較貧困<!--inhabit more minorities（這裡的minorities不好翻，先跳過）-->。其中有精神卫生需求的儿童中，有50%沒有接受评估或治疗。是否可以接觸到精神卫生服務及資源會受到許多因素的影響，例如「性別、年齡、種族或民族，以及醫療保險」。因此可能有些需要接受ADHD診斷的兒童永遠無法獲得確診，也不會出現在盛行率的數據中<ref name="Sciutto, M. J. 2007"/>。

在2005年，美國的教師中有82%認為ADHD有過度診斷的情形，而3%認為有ADHD診斷不足的情形。在中國有19%的教師認為ADHD有過度診斷，而57%認為有ADHD診斷不足的情形<ref>{{cite journal |vauthors=Norvilitis JM, Fang P |title=Perceptions of ADHD in China and the United States: a preliminary study |journal=J Atten Disord |volume=9 |issue=2 |pages=413–24 |date=November 2005 |pmid=16371664 |doi=10.1177/1087054705281123 |url=}}</ref>。

==治療==
[[注意力不足過動症的治療|注意力不足過動症治療]]的建議會隨國家而不同，一般會包括[[心理治療|心理治療]]、生活方式的調整、以及藥物<ref name=NIH2016>{{cite web|title=Attention Deficit Hyperactivity Disorder|url=http://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd/index.shtml|website=National Institute of Mental Health|accessdate=2016-03-05|archive-url=https://web.archive.org/web/20160723192735/http://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd/index.shtml|archive-date=2016-07-23|dead-url=no}}</ref>。英國醫學指南建議在治療兒童ADHD時，只有在症狀嚴重時才能用藥物作為第一線的治療方式，若症狀中等，需在進行心理治療無法改善症狀，或是再度進行進行心理治療才考慮使用藥物<ref name="NICE 2009">{{citation|title=Attention Deficit Hyperactivity Disorder: Diagnosis and Management of ADHD in Children, Young People and Adults|author=National Collaborating Centre for Mental Health|publisher=British Psychological Society|isbn=9781854334718|year=2009|pages=19–27, 38, 130, 133, 317}}</ref>。加拿大及美國的醫學指南則建議藥物及行為治療並用來作為第一線的治療方式，但學齡前的兒童不建議用藥物治療<ref name=CADDRA>{{citation|title=Canadian ADHD Practice Guidelines|url=http://www.caddra.ca/cms4/pdfs/caddraGuidelines2011Introduction.pdf|publisher=Canadian ADHD Alliance|accessdate=2011-02-04}}</ref><ref name=cdc>{{citation|title=Attention-Deficit/Hyperactivity Disorder (ADHD): Recommendations|url=http://www.cdc.gov/ncbddd/adhd/guidelines.html|publisher=Centers for Disease Control and Prevention|accessdate=2015-07-13|date=2015-06-24|archive-url=https://web.archive.org/web/20150707181535/http://www.cdc.gov/ncbddd/adhd/guidelines.html|archive-date=2015-07-07|dead-url=no}}</ref>。
===中樞神經刺激劑===
{{le|美國國家心理衛生研究院|National Institute of Mental Health}}建議將中樞神經刺激劑納入ADHD治療方式中，並認為「在醫療監督使用下，利用中樞神經刺激劑治療可以視為是安全的。」<ref name=NIMH>{{cite web |url=http://www.nimh.nih.gov/health/publications/attention-deficit-hyperactivity-disorder/medications.shtml |title=NIMH · ADHD · The Treatment of ADHD |work= |accessdate= |archive-url=https://web.archive.org/web/20090510234423/http://www.nimh.nih.gov/health/publications/attention-deficit-hyperactivity-disorder/medications.shtml |archive-date=2009-05-10 |dead-url=no }}</ref>2007年有針對藥物的類別審查，在常處方的中樞神經刺激劑中，沒有發現藥效差異或是不良副作用的證據<ref>McDonagh MS, Peterson K, Dana T, Thakurta S. (2007). Drug Class Review on Pharmacologic Treatments for ADHD. [http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=adhd.chapter.53 Results]{{dead link|date=December 2016 |bot=InternetArchiveBot |fix-attempted=yes }}：「沒有證據可以證實研究的藥物在藥效上有差異，或是有{{le|不良事件|adverse event}}。」</ref>

1993年到2003年之間，全世界ADHD藥物的使用量成長到將近原來的三倍<ref name=NIMH2007>{{cite web | url=http://www.nimh.nih.gov/news/science-news/2007/global-use-of-adhd-medications-rises-dramatically.shtml | title=Global Use of ADHD Medications Rises Dramatically | publisher=NIMH | accessdate=2013-05-06 | archive-url=https://web.archive.org/web/20130512105530/http://www.nimh.nih.gov/news/science-news/2007/global-use-of-adhd-medications-rises-dramatically.shtml | archive-date=2013-05-12 | dead-url=yes }}</ref>，大部份的ADHD藥物是在美國開立的處方<ref name = NIMH2007/>。在1990年代，全球[[哌甲酯|哌甲酯]]和[[右旋安非他命|右旋安非他命]]的用量中，美國佔了90%，2000年代初期，因為其他國家的使用量增加，因此美國使用量的比例降到80%<ref name=USE2003>{{cite journal|last=Marwick|first=C.|date=2003-01-11|title=US doctor warns of misuse of prescribed stimulants|journal=BMJ|location=Washington, DC|volume=326|issue=7380|page=67|issn=0959-8138|doi=10.1136/bmj.326.7380.67|pmc=1125021|pmid=12521954|url=http://www.bmj.com/cgi/content/extract/326/7380/67}}</ref>{{better source|date=2018年4月}}，但[[聯合國毒品和犯罪問題辦公室|聯合國毒品和犯罪問題辦公室]]提出的2006年世界藥品報告中，提出美國只佔全球右旋安非他命使用量的17%<ref name="World Drug Report" />。2003年時，英國醫師所開立的哌甲酯處方箋只佔美國的1/10，而法國及義大利所開立中樞神經刺激劑的處方箋只佔美國的1/20<ref name=USE2003/>。而2006年世界藥品報告中也提到在2000年初期，已有許多歐洲國家將安非他命列為治療用藥物<ref name="World Drug Report">{{cite web | vauthors = Chawla S, Le Pichon T | title = World Drug Report 2006 | year = 2006 | pages = 143–144 | work = United Nations Office on Drugs and Crime | url = http://www.unodc.org/pdf/WDR_2006/wdr2006_volume1.pdf | accessdate = 2 November 2013 | archive-url = https://web.archive.org/web/20130530231143/http://www.unodc.org/pdf/WDR_2006/wdr2006_volume1.pdf | archive-date = 2013-05-30 | dead-url = no }}</ref>。

1999年針對四個美國社區1285名兒童及其家長的研究指出，之前的12個月內，有12.5%符合ADHD標準的兒童有接受中樞神經刺激劑的藥物治療<ref>{{cite journal |vauthors=Jensen PS, Kettle L, Roper MT |title=Are stimulants overprescribed? Treatment of ADHD in four U.S. communities |journal=Journal of the American Academy of Child and Adolescent Psychiatry |volume=38 |issue=7 |pages=797–804 |date=July 1999  |pmid=10405496 |doi=10.1097/00004583-199907000-00008|display-authors=etal}}</ref>。2000年5月，美國緝毒局（負責管制毒品及管制藥品）副總監Terrance Woodworth的證詞提到藥品利他能的總生產量已從1990年的1,768公斤增加到2000年的14,957公斤。此外IMS Health也提出Adderall的處方數量已從1996年的130萬劑增加到1999年的將近600萬劑<ref name=STI2013>{{cite web | url = https://www.pbs.org/wgbh/pages/frontline/shows/medicating/drugs/stats.html | title = Statistics on Stimulant Use | publisher = Public Broadcasting Service | accessdate = 31 March 2013 | archive-url = https://web.archive.org/web/20130525081134/http://www.pbs.org/wgbh/pages/frontline/shows/medicating/drugs/stats.html | archive-date = 2013-05-25 | dead-url = no }}</ref>。

====不良影響====
有些家長以及專業人士針對中樞神經刺激劑藥物的副作用以及長期使用提出質疑<ref>{{cite journal |vauthors=Lakhan SE, Hagger-Johnson GE |title=The impact of prescribed psychotropics on youth |journal=Clin Pract Epidemol Ment Health |volume=3 |issue= 1|pages=21 |year=2007 |pmid=17949504 |pmc=2100041 |doi=10.1186/1745-0179-3-21 |url=}}</ref>。而[[核磁共振|核磁共振]]研究指出長期用苯丙胺或是哌甲酯治療，會減少一些ADHD患者常見的腦部結構及機能異常，並且可提昇右[[尾状核|尾状核]]的機能<ref name="Neuroplasticity 1">{{cite journal |vauthors=Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K |title=Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects |journal=JAMA Psychiatry |volume=70 |issue=2 |pages=185–198 |date=February 2013 |pmid=23247506 |doi=10.1001/jamapsychiatry.2013.277 |url=}}</ref><ref name="Neuroplasticity 2">{{cite journal |vauthors=Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N, Lomedico A, Faraone SV, Biederman J |title=Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies |journal=J. Clin. Psychiatry |volume=74 |issue=9 |pages=902–917 |date=September 2013 |pmid=24107764 |doi=10.4088/JCP.12r08287 |url= |pmc=3801446}}</ref><ref name="Neuroplasticity 3">{{cite journal | title=Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects. | journal=Acta psychiatrica Scand. | date=February 2012 | volume=125 | issue=2 | pages=114–126 | pmid=22118249 |vauthors=Frodl T, Skokauskas N | quote=Basal ganglia regions like the right globus pallidus, the right putamen, and the nucleus caudatus are structurally affected in children with ADHD. These changes and alterations in limbic regions like ACC and amygdala are more pronounced in non-treated populations and seem to diminish over time from child to adulthood. Treatment seems to have positive effects on brain structure. | doi=10.1111/j.1600-0447.2011.01786.x}}</ref>。

[[美国食品药品监督管理局|美国食品药品监督管理局]]（USFDA）曾在2006年2月9日投票通過針對治療ADHD的中樞神經刺激劑藥品加註黑框警告，說明有可能增加心血管疾病的風險<ref>{{cite journal |author=Nissen SE |title=ADHD drugs and cardiovascular risk |journal=N. Engl. J. Med. |volume=354 |issue=14 |pages=1445–8 |date=April 2006 |pmid=16549404 |doi=10.1056/NEJMp068049 |url=http://content.nejm.org/cgi/content/extract/354/14/1445 |access-date=2008-09-16 |archive-url=https://web.archive.org/web/20081012054020/http://content.nejm.org/cgi/content/extract/354/14/1445 |archive-date=2008-10-12 |dead-url=no }}</ref>。後來USFDA委託的研究指出，不論是在兒童、青少年或是成年人，嚴重的不良心血管事件（[[心搏停止|心搏停止]]、[[心肌梗死|心肌梗死]]或是[[中風|中風]]）和苯丙胺或其他ADHD治療用中樞神經刺激劑的使用沒有相關性<ref>{{cite web | title=FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults | date=20 December 2011 | url=http://www.fda.gov/Drugs/DrugSafety/ucm277770.htm | work=United States Food and Drug Administration | accessdate=4 November 2013 | archive-url=https://web.archive.org/web/20131030042927/http://www.fda.gov/Drugs/DrugSafety/ucm277770.htm | archive-date=2013-10-30 | dead-url=no }}</ref><ref name="pmid22043968">{{cite journal |vauthors=Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell FA, Ray WA | title = ADHD drugs and serious cardiovascular events in children and young adults | journal = N. Engl. J. Med. | volume = 365 | issue = 20 | pages = 1896–1904 |date=November 2011 | pmid = 22043968 | pmc = 4943074 | doi = 10.1056/NEJMoa1110212 }}</ref><ref>{{cite web | title=FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults | date=15 December 2011 | url=http://www.fda.gov/Drugs/DrugSafety/ucm279858.htm | work=United States Food and Drug Administration | accessdate=4 November 2013 | archive-url=https://web.archive.org/web/20131030064843/http://www.fda.gov/Drugs/DrugSafety/ucm279858.htm | archive-date=2013-10-30 | dead-url=no }}</ref><ref name="pmid22161946">{{cite journal |vauthors=Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV | title = ADHD medications and risk of serious cardiovascular events in young and middle-aged adults |date=December 2011 | journal = JAMA | volume = 306 | issue = 24 | pages = 2673–2683 | pmid = 22161946 | pmc = 3350308 | doi = 10.1001/jama.2011.1830 }}</ref>。

苯丙胺及哌甲酯對於基因調節的影響和劑量及給藥方式有關<ref name="Addiction genetics">{{cite journal |vauthors=Steiner H, Van Waes V |title=Addiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulants |journal=Prog. Neurobiol. |volume=100 |issue= |pages=60–80 |date=January 2013  |pmid=23085425 |pmc=3525776 |doi=10.1016/j.pneurobio.2012.10.001 |url=}}</ref>。大部份基因調節和過動的研究是以動物實驗為基礎，在實驗中注射高劑量的苯丙胺<ref name="Addiction genetics" />。有少數研究是用（依體重比例）等效人體治療劑量及口服給藥，兩者的效果即使有差異，差異也非常的小<ref name="Addiction genetics" />。若是因為腦部發展或是心理疾病，需長期使用哌甲酯，其長期對人體影響還不清楚。不過美國二歲到六歲的兒童中，有0.51%至1.23%有服用中樞神經刺激劑的藥物。而尚未獲准對這些年齡層使用中樞神經刺激劑來進行治療<ref>{{cite journal |vauthors=Kimko HC, Cross JT, Abernethy DR |title=Pharmacokinetics and clinical effectiveness of methylphenidate |journal=Clin Pharmacokinet |volume=37 |issue=6 |pages=457–70 |date=December 1999 |pmid=10628897 |doi= 10.2165/00003088-199937060-00002|url=}}</ref><ref>{{cite journal |author=Vitiello B |title=Psychopharmacology for young children: clinical needs and research opportunities |journal=Pediatrics |volume=108 |issue=4 |pages=983–9 |date=October 2001 |pmid=11581454 |doi=10.1542/peds.108.4.983 |url=http://pediatrics.aappublications.org/cgi/content/full/108/4/983 |access-date=2009-04-27 |archive-url=https://web.archive.org/web/20081010122400/http://pediatrics.aappublications.org/cgi/content/full/108/4/983 |archive-date=2008-10-10 |dead-url=no }}</ref>。

有些情形下，在接受中樞神經刺激劑治療時，其身高及體重的成長會較正常值要低，若停止中樞神經刺激劑治療，身高及體重的成長會恢復到正常的範圍<ref name="Millichap">{{cite book | author = Millichap JG |  editor = Millichap JG | title = Attention Deficit Hyperactivity Disorder Handbook: A Physician's Guide to ADHD | year = 2010 | publisher = Springer | location = New York, US | isbn = 9781441913968 | pages = 121–123, 125–127 | edition = 2nd | chapter = Chapter 9: Medications for ADHD | quote = Ongoing research has provided answers to many of the parents’ concerns, and has confirmed the effectiveness and safety of the long-term use of medication.}}</ref><ref name="Long-Term Outcomes Medications">{{cite journal |vauthors=Huang YS, Tsai MH | title = Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge | journal = CNS Drugs | volume = 25 | issue = 7 | pages = 539–554 |date=July 2011  | pmid = 21699268 | doi = 10.2165/11589380-000000000-00000 | quote = Recent studies have demonstrated that stimulants, along with the non-stimulants atomoxetine and extended-release guanfacine, are continuously effective for more than 2-year treatment periods with few and tolerable adverse effects.}}</ref><ref name="pmid18295156">{{cite journal | author = Vitiello B | title = Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function | journal = Child Adolesc. Psychiatr. Clin. N. Am. | volume = 17 | issue = 2 | pages = 459–474 |date=April 2008 | pmid = 18295156 | pmc = 2408826 | doi = 10.1016/j.chc.2007.11.010 }}</ref>。若持續接受了三年的中樞神經刺激劑治療，成年時身高平均會減少二公分<ref name="pmid18295156" />。

====效果====
臨床中樞神經刺激劑研究的回顧研究，已經確定長期用苯丙胺治療ADHD的安全性及效果<ref name="Millichap_3">{{cite book | author = Millichap JG |  editor = Millichap JG | title = Attention Deficit Hyperactivity Disorder Handbook: A Physician's Guide to ADHD | year = 2010 | publisher = Springer | location = New York | isbn = 9781441913968 | pages = 111–113 | edition = 2nd | chapter = Chapter 3: Medications for ADHD}}</ref><ref name="ADHD">{{cite web | title=Stimulants for Attention Deficit Hyperactivity Disorder | url=http://www.webmd.com/add-adhd/childhood-adhd/stimulants-for-attention-deficit-hyperactivity-disorder | work=WebMD | publisher=Healthwise | date=12 April 2010 | accessdate=12 November 2013 | archive-url=https://web.archive.org/web/20131113004717/http://www.webmd.com/add-adhd/childhood-adhd/stimulants-for-attention-deficit-hyperactivity-disorder | archive-date=2013-11-13 | dead-url=no }}</ref><ref name="Safety">{{cite journal |vauthors=Chavez B, Sopko MA, Ehret MJ, Paulino RE, Goldberg KR, Angstadt K, Bogart GT |title=An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder |journal=Ann. Pharmacother. |volume=43 |issue=6 |pages=1084–1095 |date=June 2009 |pmid=19470858 |doi=10.1345/aph.1L523 |url=}}</ref>。有一個证据回顧注意到一個針對瑞典兒童進行的[[随机对照试验|随机对照试验]]，是用苯丙胺治療ADHD進行九個月的時間<ref name="Millichap" />。在治療中，兒童的專注力、破壞性行為、多動症狀都有改善，且[[智商|智商]]平均增加了4.5<ref name="Millichap" />。研究也注意到接受研究的個案中，有高比例是有ADHD的{{le|共患病|Comorbidity}}，因此推測若患者的共患病較輕微，長期的ADHD治療可能會更有機能上的改善<ref name="Millichap" />。

一篇2008年的回顧指出使用中樞神經刺激劑治療兒童會提高家長及老師對其行為的評比，但不會提昇學業表現<ref name="TI2008">{{cite web |url=http://www.ti.ubc.ca/newsletter/what-evidence-using-cns-stimulants-treat-adhd-children |title=What is the evidence for using CNS stimulants to treat ADHD in children? |accessdate=2011-03-20 |work= |publisher= |date=March–May 2008 |archive-url=https://web.archive.org/web/20110821042905/http://www.ti.ubc.ca/newsletter/what-evidence-using-cns-stimulants-treat-adhd-children |archive-date=2011-08-21 |dead-url=no }}</ref>。同樣的研究也發現，接受治療三年以上的兒童，其發育會較未治療的兒童要慢<ref name="TI2008"/>。14個月的密集治療不影響八年後的長期療效<ref name="Molina et al 2009">{{cite journal |author=Molina BS |title=The MTA at 8 Years: Prospective Follow-Up of Children Treated for Combined Type ADHD in a Multisite Study |journal=J Am Acad Child Adolesc Psychiatry |volume= 48|issue= 5|pages= 484–500|date=March 2009 |pmid=19318991 |doi=10.1097/CHI.0b013e31819c23d0 |url= |pmc=3063150 |name-list-format=vanc |author2=Hinshaw SP |author3=Swanson JM |display-authors=3 |last4=Arnold |first4=L. Eugene |last5=Vitiello |first5=Benedetto |last6=Jensen |first6=Peter S. |last7=Epstein |first7=Jeffery N. |last8=Hoza |first8=Betsy |last9=Hechtman |first9=Lily |first10=Howard B. |last10=Abikoff |first11=Glen R. |last11=Elliott |first12=Laurence L. |last12=Greenhill |first13=Jeffrey H. |last13=Newcorn |first14=Karen C. |last14=Wells |first15=Timothy |last15=Wigal |first16=Robert D. |last16=Gibbons |first17=Kwan |last17=Hur |first18=Patricia R. |last18=Houck |last19=The MTA Cooperative Group}}</ref>。在各種藥物的療效及副作用上，沒有找到顯著的差異<ref name="hta.ac.uk">{{cite journal|author=King S |title=A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents |journal=Health Technol Assess |volume=10 |issue=23 |pages=iii–iv, xiii–146 |date=July 2006 |pmid=16796929 |doi=10.3310/hta10230 |url=http://www.hta.ac.uk/execsumm/summ1023.htm |nopp=true |name-list-format=vanc |author2=Griffin S |author3=Hodges Z |display-authors=3 |last4=Weatherly |first4=H |last5=Asseburg |first5=C |last6=Richardson |first6=G |last7=Golder |first7=S |last8=Taylor |first8=E |last9=Drummond |first9=M |last10=Riemsma |first10=R |deadurl=yes |archiveurl=https://web.archive.org/web/20090815091925/http://www.hta.ac.uk/execsumm/summ1023.htm |archivedate=2009-08-15 }}</ref><ref>{{cite journal |author=Brown RT |title=Treatment of attention-deficit/hyperactivity disorder: overview of the evidence |journal=Pediatrics |volume=115 |issue=6 |pages=e749–57 |date=June 2005 |pmid=15930203 |doi=10.1542/peds.2004-2560 |url= |name-list-format=vanc |author2=Amler RW |author3=Freeman WS |display-authors=3 |last4=Perrin |first4=JM |last5=Stein |first5=MT |last6=Feldman |first6=HM |last7=Pierce |first7=K |last8=Wolraich |first8=ML |author9=American Academy of Pediatrics Committee on Quality Improvement }}</ref>。

====學校的態度====
有些學校試著要求學生在就學前就接受ADHD的藥物治療<ref name=Coercion>{{cite web|url=http://www.webmd.com/add-adhd/news/20051116/schools-cant-require-adhd-drugs|title=Schools Can't Require ADHD Drugs|format=|work=|accessdate=|archive-url=https://web.archive.org/web/20100425234021/http://www.webmd.com/add-adhd/news/20051116/schools-cant-require-adhd-drugs|archive-date=2010-04-25|dead-url=no}}</ref>。美國已通過法案反對這項措施<ref name=Coercion/>。

====誤用的濳在風險====
用來治療ADHD的中樞神經刺激劑在美國列為第二階段管制物質<ref>{{cite journal|url=http://pn.psychiatryonline.org/cgi/content/full/36/21/20 |author=Jim Rosack |title=Controversy Erupts Over Ads for ADHD Drugs |volume=36 |issue=21 |pages=20–21 |journal=Psychiatr News |format= |accessdate= |doi=10.1176/pn.36.21.0020 |year=2001 }}{{dead link|date=October 2016 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>。爭議的焦點在於哌甲酯濫用的比例是否和其他的中樞神經刺激劑相當。有些研究者{{who|date=2017-09}}認為其濫用比例較其他的中樞神經刺激劑要少很多，不過目前研究指出根據其濫用評比分數，其誤用的濳在風險和[[可卡因|可卡因]]及[[d-苯丙胺|d-苯丙胺]]相近<ref>{{cite journal |vauthors=Kollins SH, MacDonald EK, Rush CR |title=Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review |journal=Pharmacol. Biochem. Behav. |volume=68 |issue=3 |pages=611–27 |date=March 2001 |pmid=11325419 |doi=10.1016/S0091-3057(01)00464-6 |url=http://linkinghub.elsevier.com/retrieve/pii/S0091-3057(01)00464-6 |author= |access-date=2009-04-27 |archive-url=https://web.archive.org/web/20180728221754/https://linkinghub.elsevier.com/retrieve/pii/S0091-3057(01)00464-6 |archive-date=2018-07-28 |dead-url=no }}</ref>。

不論兒童是否有患有ADHD，都有中樞神經刺激劑濫用的風險，而有ADHD的人，其濫用中樞神經刺激劑藥物或是將藥物轉手給其他人的風險最高。根據2008年的元分析，美國國小，中學的學生中有5%至9%有服用非處方的中樞神經刺激劑，大學生中則有5%至35%。其中大部份服用的原因是為了提昇專注力、提高警覺性<!--"get high,"-->或是進行實驗<ref name="Wilens TE, Adler LA, Adams J, et al. 2008 21–31">{{cite journal |author=Wilens TE |title=Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature |journal=J Am Acad Child Adolesc Psychiatry |volume=47 |issue=1 |pages=21–31 |date=January 2008 |pmid=18174822 |doi=10.1097/chi.0b013e31815a56f1 |url= |name-list-format=vanc |author2=Adler LA |author3=Adams J |display-authors=3 |last4=Sgambati |first4=Stephanie |last5=Rotrosen |first5=John |last6=Sawtelle |first6=Robert |last7=Utzinger |first7=Linsey |last8=Fusillo |first8=Steven}}</ref>。

病患可能會將中樞神經刺激劑處方藥當作[[娛樂性藥物|娛樂性藥物]]賣出，而有些沒有ADHD的學生會有[[哌甲酯|哌甲酯]]（Ritalin）作為學習時的輔助藥物<ref>{{cite news |url=http://edition.cnn.com/2001/HEALTH/children/01/08/college.ritalin/ |title=Ritalin abuse scoring high on college illegal drug circuit |format= |work=CNN |accessdate=2010-04-25 |date=2001-01-08 |archive-url=https://web.archive.org/web/20110522124300/http://edition.cnn.com/2001/HEALTH/children/01/08/college.ritalin/ |archive-date=2011-05-22 |dead-url=no }}</ref>。中樞神經刺激劑的非處方使用比例很高。2003年的研究發現前一年美國大學中有4.1%的學生使用非處方的中樞神經刺激劑<ref>{{cite journal |vauthors=McCabe SE, Knight JR, Teter CJ, Wechsler H |title=Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey |journal=Addiction (Abingdon, England) |volume=100 |issue=1 |pages=96–106 |date=January 2005 |pmid=15598197 |doi=10.1111/j.1360-0443.2005.00944.x |url=}}</ref>。

2008年球季，[[美國職業棒球大聯盟|美國職業棒球大聯盟]]有近8%選手持有ADHD的診斷證明，大聯盟授權他們可以服用[[中樞神經刺激劑|中樞神經刺激劑]]治療，聯盟的勞工關係行政副主席Rob Manfred表示因為大聯盟選手都是男性，且平均年齡較低，其數據不適合和與全國ADHD的數據來比較<ref name=espn>{{Cite web |url=http://www.espn.com/mlb/news/story?id=3822193 |title=ADHD exemptions on rise in MLB |access-date=2017-06-29 |archive-url=https://web.archive.org/web/20180319195603/http://www.espn.com/mlb/news/story?id=3822193 |archive-date=2018-03-19 |dead-url=no }}</ref>（ADHD在國際成人族群的[[盛行率|盛行率]]為：3~5%<ref name="Thomas Sanders Doust Beller 2015 pp. e994–e1001">{{cite journal | last=Thomas | first=R. | last2=Sanders | first2=S. | last3=Doust | first3=J. | last4=Beller | first4=E. | last5=Glasziou | first5=P. | title=Prevalence of Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis | journal=PEDIATRICS | publisher=American Academy of Pediatrics (AAP) | volume=135 | issue=4 | year=2015 | pages=e994–e1001 | url=https://doi.org/10.1542%2Fpeds.2014-3482 | doi=10.1542/peds.2014-3482 | accessdate=2017-04-21|quote=7.2% (95% confidence interval: 6.7 to 7.8)}}</ref>）。而美國職棒大聯盟選手ADHD比率的上昇（2007~2008球季）和該盟在2006年發布[[兴奋剂|兴奋剂]]的禁令時間重疊，因此當時有些論點認為可能有部份選手藉由模仿ADHD的症狀、或是偽造其相關病史來躲避大聯盟對於兴奋剂的禁令<ref>{{cite web|url=http://www.slate.com/id/2208429/|title=Doping Deficit Disorder: Need performance-enhancing drugs? Claim ADHD|first=William|last=Saletan|website=Slate|publisher=The Slate Group LLC|date=2009-01-12|accessdate=2009-05-02| archiveurl=https://web.archive.org/web/20090521114505/http://www.slate.com/id/2208429/| archivedate= 2009-05-21 |deadurl= no}}</ref>

==利益衝突==
FDA在2008年時曾針對五家[[藥品|藥品]]公司，有關ADHD藥品的假[[廣告|廣告]]及不恰當的行銷資料提出警告<ref>{{cite web|url=http://www.pharmalot.com/2008/09/fda-warns-five-drugmakers-over-adhd-ads/ |archive-url=https://archive.is/20120908113301/http://www.pharmalot.com/2008/09/fda-warns-five-drugmakers-over-adhd-ads/ |dead-url=yes |archive-date=2012-09-08 |title=FDA Warns Five Drugmakers Over ADHD Ads // Pharmalot |format= |work= |accessdate= }}</ref>。FDA在2008年9月发送通知給[[诺华公司|诺华公司]]及[[強生公司|強生公司]]，因為他們在{{le|盐酸右哌甲酯|Dexmethylphenidate|Focalin XR}}及[[哌甲酯#專思達|專思達]]的廣告上誇大藥物的效果<ref>{{cite web|url=http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2008/ucm1048118.htm|title=Focalin  XR (dexmethylphenidate hydrochloride) extended-release capsules CII|date=2008-09-25|work=Warning Letters|publisher=U.S. Food and Drug Administration|accessdate=2009-08-05|archive-url=https://www.webcitation.org/68JlJjSGb?url=http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2008/ucm1048118.htm|archive-date=2012-06-10|dead-url=no}}</ref><ref>{{cite web|url=http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2008/ucm1048119.htm|title=CONCERTA (methylphenidate HCI) Extended-release Tablets CII|date=2008-09-25|work=Warning Letters|publisher=U.S. Food and Drug Administration|accessdate=2009-08-05|archive-url=https://web.archive.org/web/20100308115640/http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2008/ucm1048119.htm|archive-date=2010-03-08|dead-url=no}}</ref>。FDA也因為[[Adderall|Adderall XR]]的廣告，寄送了類似的通知給{{le|Shire藥廠|Shire plc}}<ref>{{cite web|url=http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2008/ucm1048117.htm|title=Adderall XR Capsules|date=2008-09-25|work=Warning Letters|publisher=U.S. Food and Drug Administration|accessdate=2009-08-05|archive-url=https://web.archive.org/web/20110606093731/http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2008/ucm1048117.htm|archive-date=2011-06-06|dead-url=no}}</ref>。

[[罗素·巴克利|罗素·巴克利]]是著名的ADHD研究者，也發表過ADHD的診斷指南，但因為曾經收受藥廠的演講費及顧問費，因此{{le|緩慢認知風格|Sluggish cognitive tempo|其研究}}也受到批評<!--[[Sluggish_cognitive_tempo#Controversy|criticized for his works]]--><ref name=ProPublica>{{cite web|title=Has Your Health Professional Received Drug Company Money?|url=http://projects.propublica.org/docdollars/search?utf8=_&term=barkley&state%5Bid%5D=41&company%5Bid%5D=&period%5B%5D=&services%5B%5D=|work=ProPublica|accessdate=2014-04-17|archive-url=https://web.archive.org/web/20140417024204/http://projects.propublica.org/docdollars/search?utf8=_&term=barkley&state%5Bid%5D=41&company%5Bid%5D=&period%5B%5D=&services%5B%5D=|archive-date=2014-04-17|dead-url=no}}</ref> 。

哈佛醫學院的{{le|約瑟夫·貝德曼|Joseph Biederman}}是ADHD醫學專家，論文常被引用，但在2008年時發現他在2000年至2007年有收受藥廠$160萬美元，沒有向哈佛醫學院核備<ref name=Adams2008>{{cite journal|author=Adams G.|title=Harvard medics "concealed drug firm cash"|journal=The Independent|volume=|issue=|pages=|date=9 July 2008|pmid=|doi=|url=https://www.independent.co.uk/news/world/americas/harvard-medics-concealed-drug-firm-cash-842792.html|location=London|accessdate=2010-04-25|archive-url=https://web.archive.org/web/20100505212951/http://www.independent.co.uk/news/world/americas/harvard-medics-concealed-drug-firm-cash-842792.html|archive-date=2010-05-05|dead-url=no}}</ref><ref name=NYT2008>{{cite news | url=https://www.nytimes.com/2008/06/08/us/08conflict.html?ex=1213502400&en=23737184f344c4ca&ei=5070&emc=eta1 | title=Researchers Fail to Reveal Full Drug Pay | format= | work=The New York Times | accessdate=2010-04-25 | first1=Gardiner | last1=Harris | first2=Benedict | last2=Carey | date=2008-06-08 | archive-url=https://web.archive.org/web/20080611030247/http://www.nytimes.com/2008/06/08/us/08conflict.html?ex=1213502400&en=23737184f344c4ca&ei=5070&emc=eta1 | archive-date=2008-06-11 | dead-url=no }}</ref>。斯坦利醫學研究所（Stanley Medical Research Institute）有資助精神醫學的研究，其執行董事{{le|E. Fuller Torrey|E. Fuller Torrey}}提到：「特別在兒童精神醫學的領域，我們知道的真的太少，我們迫切的需要研究可以不受行業資金所影響。」<ref name=NYT2008/>

[[CHADD|CHADD]]（Children and Adults with Attention-Deficit/Hyperactivity Disorder）是位於马里兰州Landover的ADHD倡議組織，2007年所接受的醫療協助，佔其預算116.9萬美元的26%<ref>{{cite web |url=http://www.chadd.org/AM/Template.cfm?Section=Reports1&Template=/CM/ContentDisplay.cfm&ContentID=5148 |title=CHADD’s Income and Expenditures (2006–2007) |format=PDF |work= |author=Susan Buningh |accessdate= |archive-url=https://web.archive.org/web/20090215012357/http://www.chadd.org/AM/Template.cfm?Section=Reports1&Template=%2FCM%2FContentDisplay.cfm&ContentID=5148 |archive-date=2009-02-15 |dead-url=no }}</ref>。

==標籤和污名化==
[[羅素·巴克利|羅素·巴克利]]認為ADHD的標籤是兩面刃，標籤有許多的缺點，但是若是準確的識別（及標籤），當事人可以接觸到需要的醫療服務。他也認為標籤也可以幫助個人瞭解其診斷，配合實證為基礎的資訊下，針對如何應對診斷結果有最好的決定<ref name="autogenerated5">[https://www.pbs.org/wgbh/pages/frontline/shows/medicating/interviews/barkley.html PBS – frontline: medicating kids: interviews: russell barkley] {{webarchive |url=https://web.archive.org/web/20160731120422/http://www.pbs.org/wgbh/pages/frontline/shows/medicating/interviews/barkley.html |date=July 31, 2016 }}</ref>。進一步的研究指出兄弟姊妹及家長的教育至少對於短期治療的結果上是有幫助的<ref name="autogenerated3A">Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder {{cite web |url=http://www.aacap.org/galleries/PracticeParameters/JAACAP_ADHD_2007.pdf |title=Archived copy |accessdate=2008-10-09 |deadurl=yes |archiveurl=https://web.archive.org/web/20081217120625/http://www.aacap.org/galleries/PracticeParameters/JAACAP_ADHD_2007.pdf |archivedate=2008-12-17 |df= }}</ref>。巴克利也提到ADHD的權利「...因為已通過許多的法案保護這一群人，在特殊的教育法案（例如[[美国残疾人法案|美国残疾人法案]]）中，有提到ADHD符合其中的條件。若是改變了這様的標籤，再將此視為只是正常氣質下的一些變異，這些人就失去了符合他們需要的服務，也喪失了這些努力之後才獲得的保護，原來讓他們可以不會被歧視的保護...」<ref name="autogenerated5" />。建立CHADD的精神科醫生{{le|哈維·帕克|Harvey Parker}}則認為：「我們應該為了全美國的學校開始瞭解及認識ADHD的兒童，也開始去尋找治療方式而慶賀。我們應該為了大眾不再看待ADHD的兒童是「壞小孩」，而看成是有困難的兒童（而且是可以處理/改善的困難）而慶賀。」<ref>[https://www.pbs.org/wgbh/pages/frontline/shows/medicating/interviews/parker.html PBS – frontline: medicating kids: interviews: harvey parker] {{webarchive |url=https://web.archive.org/web/20160311133217/http://www.pbs.org/wgbh/pages/frontline/shows/medicating/interviews/parker.html |date=March 11, 2016 }}</ref>。不過兒童在學校中，常會因為使用[[精神藥物|精神科藥物]]而被同學嘲笑，其中也包括ADHD的用藥<ref>{{cite journal |vauthors=Santosh PJ, Taylor E |title=Stimulant drugs |journal=European Child & Adolescent Psychiatry |volume=9 |issue=Suppl 1 |pages=I27–43 |year=2000 |pmid=11140778 |doi=10.1007/s007870070017}}</ref>。

==對於注意力不足過動症的觀點==
===歐洲國家的觀點===
有關[[注意力不足過動症|注意力不足過動症]]的定義，除了《精神疾病診斷與統計手冊》（DSM）外 ，也可以參考[[世界衛生組織|世界衛生組織]]提出《[[國際疾病與相關健康問題統計分類|國際疾病與相關健康問題統計分類]]》（ICD）中的定義<ref name=twcpa13453>{{cite web |url=http://www.twcpa.org.tw/news_detail.php?nid=13453 |language=中文 |title=注意力不足/過動症的ICF核心分類  ICF Core Set for ADHD(臺灣諮商心理學會暨東華大學人文臨床療癒學群聯合刊載 |author=李嘉玲、翁士恆 |publisher=臺灣諮商心理學會 |date=2017-01-20 |accessdate=2017-08-12 |archive-url=https://web.archive.org/web/20170812055903/http://www.twcpa.org.tw/news_detail.php?nid=13453 |archive-date=2017-08-12 |dead-url=no }}</ref>，在1992年完成的[[ICD-10_第五章：精神和行为障碍|ICD-10]]，將注意力不足過動症放在「第五章：精神和行为障碍」的「F90 過度活躍症」之下<ref>{{Cite web |url=http://apps.who.int/classifications/icd10/browse/2015/en |title=ICD F90 |access-date=2015-11-13 |archive-url=https://web.archive.org/web/20151102042503/http://apps.who.int/classifications/icd10/browse/2015/en#/F90 |archive-date=2015-11-02 |dead-url=no }}</ref>。而DSM-5的準則則是相關症狀要在12歲以前出現，ICD-10的標準較窄，相關症狀要在七歲之前就出現，因此ICD-10下的ADHD盛行率會較DSM-5下的盛行率要低<ref name=twcpa13453/>。

2009年時，英国心理学会、皇家精神医学院和英國國家健康照護專業組織合作發表一系列有關注意力不足過動症診斷及治療的指南<ref name=NICE2008>{{cite web |url=http://www.nice.org.uk/nicemedia/pdf/CG72FullGuideline.pdf |format=PDF |title=CG72 Attention deficit hyperactivity disorder (ADHD): full guideline |accessdate=2008-10-08 |work= |publisher=UK National Health Service |date=2008-09-24 |archive-url=https://web.archive.org/web/20081010075003/http://www.nice.org.uk/nicemedia/pdf/CG72FullGuideline.pdf |archive-date=2008-10-10 |dead-url=no }}</ref>。指南中回顧了Ford等人的研究，其研究發現若使用美國的DSM-IV標準，英國有3.6%的男孩及0.85%的女孩有注意力不足過動症<ref>{{cite journal |vauthors=Ford T, Goodman R, Meltzer H |title=The British Child and Adolescent Mental Health Survey 1999: the prevalence of DSM-IV disorders |journal=Journal of the American Academy of Child and Adolescent Psychiatry |volume=42 |issue=10 |pages=1203–11 |date=2003-10 |pmid=14560170 |doi=10.1097/00004583-200310000-00011}}</ref>，指南中也提到，若使用的是ICD-10中針對過度活躍症的診斷標準（此標準對ADHD的定義較窄、是歐洲主要採用標準），盛行率降到1.5%<ref name="FitzgeraldBellgrove2007">{{cite book|author1=Michael Fitzgerald|author2=Mark Bellgrove|author3=Michael Gill|title=Handbook of Attention Deficit Hyperactivity Disorder|url=https://books.google.com/books?id=LQRUM5v_N1IC|date=2007-04-30|publisher=John Wiley & Sons|isbn=978-0-470-03215-2|page=270}}</ref>。

一個2007年的系統性文獻回顧提出全世界ADHD的盛行率為5.29%，在北美及歐洲沒有顯著的差異，文獻回顧有提到非洲及中東的盛行率和北美有顯著差異，不過也提醒說這可能是因為在非洲及中東的相關研究不多所造成<ref>{{cite journal |doi=10.1176/appi.ajp.164.6.942|title=The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression Analysis |year=2007 |last1=Polanczyk |first1=G. |last2=De Lima |first2=M. S. |last3=Horta |first3=B. L. |last4=Biederman |first4=J. |last5=Rohde |first5=L. A. |journal=American Journal of Psychiatry |volume=164 |pages=942–8 |pmid=17541055 |issue=6}}</ref>。

預定於2018年發行的ICD-11 （ICD 第十一版）的初始草稿中，注意力不足過動症歸類於6A05（ADHD）的類別裡，而該注意力不足過動症類別中的定義暨介紹已趨近現時之DSM-5。<ref>{{cite web|url=https://icd.who.int/dev11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f821852937|title=ICD-11 Beta Draft|edition=11 Beta Draft|author=|date=|publisher=World Health Organization|deadurl=no|archiveurl=https://web.archive.org/web/20170202223545/http://apps.who.int/classifications/icd11/browse/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f821852937|archivedate=2017-02-02}}</ref>

英國、德國等國[[利他能|利他能]]等過動症藥物的處方數量自1990年後都有明顯上昇，有人認為是因為對子女「成績」重視所導致的結果<ref>{{cite journal|author=陳豐偉|year=2013|title=歐洲父母選擇用藥物治療過動兒，台灣會跟進嗎？|journal=商業周刊|publisher=商周集團|url=http://health.businessweekly.com.tw/AArticle.aspx?ID=ARTL000004569&p=0|date=2013-10-09|accessdate=2017-08-27|archive-url=https://web.archive.org/web/20170827211320/http://health.businessweekly.com.tw/AArticle.aspx?ID=ARTL000004569&p=0|archive-date=2017-08-27|dead-url=no}}</ref>{{Primary source-inline}}<!--[[Draft:Wikipedia:可靠來源_(醫學)#主流媒體|Draft:Wikipedia:可靠來源_(醫學)#主流媒體]]有提到：「在英文維基百科中，主流媒體的文章算是獨立的第一手來源」-->，另一個論點是因為藥物減少過動兒童、青少年意外傷害的發生率，其助益超過藥物可能帶來的重大副作用，而且藥物是價值便宜，可以快速達到基本效果的選項<ref>{{cite web |url=http://blog.eroach.net/?p=1943 |author=陳豐偉 |language=中文 |title=罹患過動症兒童與年輕人死亡率增加150% |publisher=陳豐偉醫師的高雄精神科診所札記 |date=2017-07-23 |accessdate=2017-08-27 |archive-url=https://web.archive.org/web/20170810211605/http://blog.eroach.net/?p=1943 |archive-date=2017-08-10 |dead-url=no }}</ref>。

===山達基===
Joel和Robert曾在《[[洛杉磯時報|洛杉磯時報]]》的報導中指出：「[[利他能|利他能]]（一種治療ADHD的藥品）爭議的出現幾乎是由[[山達基|山達基]]運動一手推動」<ref name="LA Times">{{cite news | first=Joel | last=Sappell | author2=Welkos, Robert W. | url=http://www.latimes.com/news/local/la-scientology062990a,1,6085874,full.story?coll=la-news-comment | title=Suits, Protests Fuel a Campaign Against Psychiatry | work=Los Angeles Times | page=A48:1 | date=1990-06-29 | accessdate=2006-11-29 | deadurl=yes | archiveurl=https://web.archive.org/web/20080304130509/http://www.latimes.com/news/local/la-scientology062990a,1,6085874,full.story?coll=la-news-comment | archivedate=2008-03-04 }} Backup copy [http://www.cs.cmu.edu/~dst/Library/Shelf/la90/la90-6b.html link here]  {{webarchive|url=https://web.archive.org/web/20160303191910/http://www.cs.cmu.edu/~dst/Library/Shelf/la90/la90-6b.html |date=2016-03-03 }}</ref>。[[公民人權委員會|公民人權委員會]]是山達基在1969年成立的[[反精神醫學|反精神醫學]]團體。於1980年代在美國發起了反對使用利他能的運動，並且遊說國會針對利他能進行調查<ref name="LA Times" />山達基出版品中曾提到「此運動真正反對的目標」是「精神醫學專業」<ref name="LA Times" />。<!--[[Scientology|Scientology]] publications claimed the "real target of the campaign" as "the psychiatric profession itself" and said that the campaign "brought wide acceptance of the fact that (the commission){{sic}}</!-- formatting as in original Times article --/> and the Scientologists are the ones effectively doing something about [...] psychiatric drugging".<ref name="LA Times" />-->。[[湯姆·克魯斯|湯姆·克魯斯]]曾認為利他能（[[哌甲酯|哌甲酯]]）及[[阿得拉尔|阿得拉尔]]藥物是「毒品」（street drugs）<ref>{{Cite news |last=Leiby |first=Richard |url=https://www.washingtonpost.com/wp-dyn/content/article/2005/06/24/AR2005062401866.html |title=A Couch Tom Cruise Won't Jump On |publisher=Washington Post |date=25 June 2005 |accessdate=22 September 2015 |archive-url=https://web.archive.org/web/20050921172739/http://www.washingtonpost.com/wp-dyn/content/article/2005/06/24/AR2005062401866.html |archive-date=2005-09-21 |dead-url=no }}</ref>。Ushma S. Neill醫師批評這種論點，指出在治療ADHD時使用的劑量不會有成癮的問題，而且有資料證實若用興奮劑治療兒童，兒童未來物質濫用的風險較低<ref name="pmid16075033">{{cite journal|last=Neill |first=Ushma S. |title=Tom Cruise is dangerous and irresponsible |journal=Journal of Clinical Investigation |volume=115 |issue=8|pages=1964–5 |date=August 2005 |pmid=16075033 |pmc=1180571 |doi=10.1172/JCI26200 |doi-access=free }}</ref>。
===其他===
英國科學家{{link-en|格林菲爾德|Susan Greenfield}}在2007年於[[英國上議院|英國上議院]]公開演說，認為需針對ADHD的診斷急劇增加以及可能的原因進行廣泛的調查。在她的演說後，[[英国广播公司|英国广播公司]]的《[[廣角鏡_(電視節目)|廣角鏡]]》有強調一些研究，這些研究認為建議的藥物在長期來說沒有比其他治療方式要好<ref>{{Cite news |url=http://news.bbc.co.uk/2/hi/health/7093944.stm |title=Peer calls for ADHD care review |publisher=BBC News |date=14 November 2007 |accessdate=29 January 2012 |archive-url=https://web.archive.org/web/20121031004031/http://news.bbc.co.uk/2/hi/health/7093944.stm |archive-date=2012-10-31 |dead-url=no }}</ref>。2010年[[英國廣播公司信托基金|英國廣播公司信托基金]]批評2007年的《廣角鏡》節目，其中將研究總結為「兒童在使用ADHD藥物三年後，其行為沒有明顯改善」，但真正的結果是「研究發現兒童在藥物一段時間後，行為會有顯著的改善」，只是藥物長期的結果「沒有比行為治療要好。」<ref>{{cite news |title=BBC must broadcast apology over inaccurate Panorama programme |last=Singh |first=Anita |url=https://www.telegraph.co.uk/news/7307972/BBC-must-broadcast-apology-over-inaccurate-Panorama-programme.html |newspaper=The Telegraph |date=25 February 2010 |accessdate=29 January 2012 |archive-url=https://web.archive.org/web/20180622222040/https://www.telegraph.co.uk/news/7307972/BBC-must-broadcast-apology-over-inaccurate-Panorama-programme.html |archive-date=2018-06-22 |dead-url=no }}</ref>。

美國共和黨参议员[[強尼·艾薩克森|強尼·艾薩克森]]在2017年時表示ADHD不是學習障礙，而是「家長不足障礙」（parental deficit disorder），是「家長沒有依應有方式教養小孩」的結果，因此被他的選民批評<ref>{{cite news|last1=Ross|first1=Kaitlyn|title=VERIFY: Did Sen. Isakson blame Attention Deficit Disorder on parents?|url=http://www.11alive.com/news/local/verify/verify-did-sen-isakson-blame-attention-deficit-disorder-on-parents/465174277|publisher=11 Alive News|date=August 17, 2017}}</ref>。

台灣在2016年7月時，因為ADHD是否要用藥的爭議，[[立法院|立法院]]舉行了「ADHD之多元探討公聽會」，其中討論ADHD用藥面向、ADHD孩子學習環境及處理方式等議題。與會的兒童及青少年[[精神科醫師|精神科醫師]]表示目前治療會依病患情形，使用[[行為治療|行為治療]]、[[藥物治療|藥物治療]]及環境支持等多元作法，也建議治療方式需要有科學證據及嚴謹的研究設計支持。而出席的[[公民人權協會|公民人權協會]]代表、以及幾位在場的中醫、小兒科醫師及營養師則反對利用藥物治療ADHD，認為可以透過飲食、環境及家庭等方式改善<ref name="legislative yuan">{{cite web
|url=https://video.udn.com/news/533636
|title=用藥爭議-立法院上演大對決 ADHD用藥爭議 立法院上演大對決
|date=2016年8月
|accessdate=2017-09-02
|website=聯合報官方網站
|language=zh-tw
|location=Taipei
|archiveurl=https://web.archive.org/web/20170902035629/https://video.udn.com/news/533636
|archivedate=2017-09-02}}</ref>。[[臺灣兒童青少年精神醫學會|臺灣兒童青少年精神醫學會]]在公聽會後發佈新聞稿表示：藥物治療本身雖有其限制，不過藥物治療是受到國際認可的有效治療方式<ref>{{cite web |author=TSCAP |url=http://www.tscap.org.tw/TW/News2/ugC_News_Detail.asp?hidNewsCatID=8&hidNewsID=104 |title=新聞稿20160412-回應質疑注意力不足過動症之診斷、藥物治療等議題 |publisher=Tscap.org.tw |date= |accessdate=2016-12-27 |archive-url=https://web.archive.org/web/20161130034950/http://www.tscap.org.tw/TW/News2/ugC_News_Detail.asp?hidNewsCatID=8&hidNewsID=104 |archive-date=2016-11-30 |dead-url=no }}</ref>。

==相關條目==
*[[注意力不足過動症#治療方式的爭議|注意力不足過動症#治療方式的爭議]]
*[[注意力不足過動症的治療#對於治療方式的不同論點（灰框內容無醫學實證支持）|注意力不足過動症的治療#對於治療方式的不同論點]]
*[[益智药|益智药]]
*《{{le|The Gene Illusion|The Gene Illusion}}》
*{{le|接受臨床研究的兒童|Children in clinical research}}
*{{le|抑鬱症的生物學|Biology of depression}}
*[[行為治療|行為治療]]

==參考資料==
{{reflist}}
==外部連結==
*{{cite web | author=巫毓荃（中央研究院歷史語言研究所助理研究員） | title=注意力不足過動症爭議的十個話題 | website=歷史學柑仔店（kám-á-tiàm） | url=http://kam-a-tiam.typepad.com/blog/2017/03/%E6%B3%A8%E6%84%8F%E5%8A%9B%E4%B8%8D%E8%B6%B3%E9%81%8E%E5%8B%95%E7%97%87%E7%88%AD%E8%AD%B0%E7%9A%84%E5%8D%81%E5%80%8B%E8%A9%B1%E9%A1%8C.html | language=zh | access-date=2018-03-18 | date=2017-03-24 | deadurl=no | archiveurl=https://web.archive.org/web/20170623235419/http://kam-a-tiam.typepad.com/blog/2017/03/%E6%B3%A8%E6%84%8F%E5%8A%9B%E4%B8%8D%E8%B6%B3%E9%81%8E%E5%8B%95%E7%97%87%E7%88%AD%E8%AD%B0%E7%9A%84%E5%8D%81%E5%80%8B%E8%A9%B1%E9%A1%8C.html | archivedate=2017-06-23<nowiki>插入非格式化文字</nowiki> }}
*{{cite web | author=Kayue | title=否定ADHD存在無助改善患者處境 | website=The News Lens 關鍵評論網 | date= | year=2018 | url=https://www.thenewslens.com/article/92079 | language=zh | access-date= | archive-url=https://web.archive.org/web/20180321132638/https://www.thenewslens.com/article/92079 | archive-date=2018-03-21 | dead-url=no }}
*{{cite web | author=林子勤／中山醫學大學附設醫院 精神科醫師 | title=從BBC的道歉啟事談起——ADHD研究結果被扭曲的過去與現在 | website=The News Lens 關鍵評論網 | date=2016-12-08 | url=https://hk.thenewslens.com/article/56252 | language=zh | access-date=2018-08-01 | archive-url=https://web.archive.org/web/20180801062151/https://hk.thenewslens.com/article/56252 | archive-date=2018-08-01 | dead-url=no }}
*{{cite web | author=林子勤 | title=社會學觀察或研究不應簡化精神科診斷標準 | website=The News Lens 關鍵評論網 | date=2016-11-26 | url=https://hk.thenewslens.com/article/55227 | language=zh | access-date=2018-08-01 | archive-url=https://web.archive.org/web/20180801062151/https://hk.thenewslens.com/article/55227 | archive-date=2018-08-01 | dead-url=no }}
{{ADHD}}
[[Category:医学争议|Category:医学争议]]
[[Category:注意力不足過動症|Category:注意力不足過動症]]